Paratek Pharmaceuticals has shared promising results from a post-marketing study of
Nuzyra (omadacycline), a comprehensive antibiotic, for treating
moderate to severe community-acquired bacterial pneumonia (CABP). This recent clinical trial, encompassing 670 patients, revealed that omadacycline met all principal and additional efficacy criteria, proving its effectiveness to be on par with moxifloxacin.
Moxifloxacin is a well-established fluoroquinolone antibiotic commonly prescribed for various
bacterial infections, including those affecting the respiratory system, skin, and eyes.
This study, labeled OPTIC-2, confirmed the effectiveness and safety of omadacycline, aligning with findings from the pivotal phase 3 OPTIC study. According to Paratek, these studies collectively form the most substantial clinical dataset for
pneumonia compared to any other antibiotic approved by the FDA over the past ten years. The trials reported high success rates, and omadacycline was generally well-received by patients, with side effects comparable to those noted in previous research.
Nuzyra distinguishes itself by being approved for both once-daily oral and intravenous administration to combat community-acquired bacterial pneumonia and severe
skin infections. Furthermore, in 2019, Paratek secured a $304 million
BARDA Project BioShield contract to develop Nuzyra as a treatment for
pulmonary anthrax.
How to obtain the latest research advancements in the field of biopharmaceuticals?
In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!
